Dr Charles Ryan steps in as President and CEO at Travecta

Travecta Therapeutics, incorporated in Singapore in 2017, has announced the appointment of Charles S. Ryan, JD, PhD as President and Chief Executive Officer (CEO). Dr Ryan recently served as CEO and Director of Neurotrope, Inc. In his new role, Dr Ryan will work closely with the scientific team to develop novel therapeutics to tackle some of the biggest challenges facing patients suffering from pain and debilitating brain disorders. The company’s current development plan anticipates its lead compound candidate for pain will be first administered to humans during the first quarter of 2022. Dr Ryan brings an extensive background in pharmaceuticals and biotechnology. Most notably, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories

(now AbbVie) for more than 10 years, where he managed several intellectual property estates. He worked closely with the commercial and development teams as well as the business development teams at Forest.